Bridge Point Capital and Huanghai Pharmaceuticals Visiting Pfizer in New Jersey Overview Huanghai Pharmaceutical is a leading player in China’s generic drug industry with a specialization in time-released medication. Its…

Overview Our client is a preeminent medical cannabis company that was founded in 2012 and launched a successful IPO in 2019 at a valuation of $1.35 billion. They have operations…